Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.36 |
| ▸ | PDE2A | O00408 | 7/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146394 | 0.89 | PDE2A (0.38) | MAPK1GPR139PDE2AAURKAAURKB | |
| SCHEMBL31146058 | 0.80 | GPR139 (0.42) | MAPK1GPR139PDE2AKDM4EALDH1A1 | |
| SCHEMBL31146221 | 0.78 | MAPK1 (0.36) | MAPK1GPR139PDE2AAURKAAURKB | |
| SCHEMBL31145972 | 0.73 | PDE2A (0.36) | MAPK1GPR139PDE2A | |
| SCHEMBL31146050 | 0.72 | GPR139 (0.42) | MAPK1GPR139PDE2AKDM4EALDH1A1 | |
| SCHEMBL31145932 | 0.71 | GPR139 (0.41) | MAPK1GPR139PDE2AKDM4EALDH1A1 | |
| SCHEMBL31146230 | 0.71 | PDE2A (0.39) | MAPK1GPR139PDE2AKMT2AHSD17B10 | |
| SCHEMBL31146112 | 0.71 | GPR139 (0.40) | MAPK1GPR139PDE2A | |
| SCHEMBL31146023 | 0.70 | PDE2A (0.34) | MAPK1GPR139PDE2AKDM4E | |
| SCHEMBL8300134 | 0.67 | CES2 (0.44) | GPR139PDE2AALDH1A1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688756-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206345-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | MAPK1 3347/4885GPR139 4045/4885PDE2A 130/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | MAPK1 1145/4885GPR139 3566/4885PDE2A 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.